Abstract
Background: Although angiotensin II type 1 receptor blockers (ARB) have beneficial effects in patients with diabetic nephropathy, they may induce a compensatory increase in renin. Renin exhibits profibrotic actions independent of angiotensin II, which is regulated by extracellular signal-regulated kinase 1 and 2 (ERK1/2). Calcitriol (1,25(OH)2D3) is a negative inhibitor of the renin-angiotensin system and the present study examined the effects of combination therapy with an ARB and 1,25(OH)2D3 on diabetic nephropathy in KK-Ay/Ta mice. Methods: KK-Ay/Ta mice were divided into four groups: ARB group, 1,25(OH)2D3 group, combination group, and control group. The urinary albumin/creatinine ratio (ACR) was measured and the renal expression of renin, p-ERK1/2 and TGF-β1 protein determined. Results: The levels of urinary ACR in the combination group were significantly lower than those in the ARB or control group. Renal expression of renin in the ARB group was significantly increased compared with the control group but was significantly decreased in both the 1,25(OH)2D3 and combination group. Renal expression of p-ERK1/2 in the combination group was significantly decreased compared with the control or ARB group. Expression of TGF-β1 protein in the ARB and combination groups, especially the combination group, was significantly decreased compared with those in the control group. Conclusions: These data suggest that the addition of 1,25(OH)2D3 to therapy with ARB further reduced proteinuria by suppressing the compensatory increase in renin expression in type 2 diabetic nephropathy. These effects might relate to suppression of renin, ERK1/2 and TGF-β1 expression which may or may not depend on angiotensin II.
Journal Section:
Original Paper
References
1.
Brewster UC, Perazella MA: The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263–272.
[PubMed]
2.
Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612–619.
[PubMed]
3.
Luft FC: Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 2002;11:59–66.
[PubMed]
4.
Wolf G: Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000;15:61–63.
[PubMed]
5.
Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
[PubMed]
6.
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
[PubMed]
7.
Muller DN, Luft FC: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221–228.
[PubMed]
8.
Huang Y, Wongamorntham S, Kasting J, et al: Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105–113.
[PubMed]
9.
Huang Y, Noble NA, Zhang J, et al: Renin stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007;72:45–52.
[PubMed]
10.
Kaneshiro Y, Ichihara A, Sakoda M, et al: Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor transgenic rats. J Am Soc Nephrol 2007;18:1789–1795.
[PubMed]
11.
Kuhlman A, Haas CS, Gross ML, et al: 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004;286:F526–F533.
[PubMed]
12.
Makibayashi K, Tatematsu M, Hirata M, et al: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001;158:1733–1741.
[PubMed]
13.
Panichi V, Migliori M, Taccola D, et al: Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001;60:87–95.
[PubMed]
14.
Schwarz U, Amman K, Orth SR, et al: Effects of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53:1696–1705.
[PubMed]
15.
Li YC, Kong J, Wei M, et al: Vitamin D: A negative endocrine regulator of the renin angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004;89–90:387–392.
16.
Yuan W, Pan W, Kong J, et al: 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007;282:29821–29830.
[PubMed]
17.
Zhang Z, Zhang Y, Ning G, et al: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008;41:15896–15901.
18.
Fan Q, Liao J, Kobayashi M, et al: Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004;19:3012–3020.
[PubMed]
19.
Ito T, Tanimoto M, Watanabe M, et al: Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology 2006;11:29–35.
[PubMed]
20.
Manucha W, Carrizo L, Ruete C, et al: Angiotensin II type 1 antagonist on oxidative stress and heat-shock protein 70 (HSP70) expression in obstructive nephropathy. Cell Mol Biol (Noisy-le grand) 2005;51:547–555.
21.
Fryer RM, Rakestraw PA, Nakane M, et al: Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 2007;106:76–81.
[PubMed]
22.
Okazaki M, Saito Y, Udaka Y, et al: Diabetic nephropathy in KK and KK-Ay mice. Exp Anim 2002;51:191–196.
[PubMed]
23.
El-Nahas AM, et al: Role of growth hormone in the development of experimental renal scarring. Kidney Int 1991;40:29–34.
[PubMed]
24.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703–713.
25.
Pfeifer M, Begerow B, Helmut W, et al: Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001;86:1633–1637.
[PubMed]
26.
Carthy E, Yamashita W, Hsu A, Ooi B: 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989;13:954–959.
[PubMed]
27.
Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy Lancet 1998;352:213–219.
28.
Perkins BA, Ficociello LH, Ostrander BE, et al: Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007;18:1353–1361.
[PubMed]
29.
Eijkelkamp WB, Zhang Z, Remuzzi G, et al: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post-hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007;18:1540–1546.
[PubMed]
30.
Nguyan G, Delarue F, Burcklé C, et al: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417–1427.
[PubMed]
31.
Cardús A, Panizo S, Parisi L, et al: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860–866.
[PubMed]
32.
Price PA, June HH, Bucley JR, et al: Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001;21:1610– 1616.
[PubMed]
33.
Li Y, Spataro BC, Yang J, et al: 1,25-Dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005;68:1500–1510.
[PubMed]
34.
Mizobuchi M, Morrissey J, Finch JL, et al: Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796–1806.
[PubMed]
35.
Hullet DA, Laeseke PF, Malin G: Prevention of chronic allograft nephropathy with vitamin D. Transpl Int 2005;18:1175–1186.
[PubMed]
36.
Parving HH, Persson F, Lewis JB, et al for the AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–2446.
[PubMed]
37.
Atsuhisa S, Hayashi K, Mitsuhide N, Takao S: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64–68.
[PubMed]
38.
Hiroyuki O, Fumio O, Kenichi I, et al: Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008;149:2816–2825.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
